Talks about one of the main reasons why they acquired Gern embryonic stem ip....'feeder free production method'. Looking forward to next weeks update about how some of these patents might be implemented into their business strategy.
-hESC's for research
-IPS cells for therapy
-Best stem cell patent estate in the world
-Over 5 subsidiaries
-Ex-Geron scientists jumping on board
-Cutting edge cryogenic technology currently being developed for tissue, organ and patient preservation.
What more can you ask for a $7 stock.
By the end of 2011 BTX will be the clear cut leader in this field IMO.
Embryonic stem cells will be the 'Gold Standard' for the research community, gonna need it to compare reprogramed somatic cells to!
BTW, Looking forward to the Stem Cell Conference in September, BTX site has it on their calendar.